ClinicalTrials.gg
RecruitingNCT06587165Updated Jun 15, 2026

Quantifying New Heart Muscle Cells

An interventional study of N15-thymidine in Tetralogy of Fallot With Pulmonary Stenosis and Heart Failure, sponsored by Weill Medical College of Cornell University. Recruiting at 4 sites in United States. Open to participants aged 30 Days to 1 Year. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
30 Days to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Heart Failure by Weill Medical College of Cornell University — 5 open to participants now, 5 under way, none of them phase 3. Heart Failure · Weill Medical College of Cornell University.

Planned enrollment
7th of 12
30 · median 40
Started
2026
with 3 others
No phase
6 of 13
2 open now
Registered
10th of 13
by date

Among the 13 studies in Heart Failure by Weill Medical College of Cornell University, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, and was the 10th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 13 studies in Heart Failure by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 30 Days to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Heart Failure by Weill Medical College of Cornell University, or all of them as a file.
02

Study summary

Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration.

The study has now been registered on ClinicalTrials.gov, despite its initiation on July 23, 2015, as registration was not mandated at the original study site, the University of Pittsburgh Medical Center. However, following the transfer of the study to Weill Cornell Medicine, adherence to institutional requirements necessitated its registration on ClinicalTrials.gov.

03

Conditions studied

  • Tetralogy of Fallot With Pulmonary Stenosis
  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
30 Days to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients at 30 days of age to 1 year of age undergoing scheduled elective cardiac surgery will be eligible for study inclusion.
  • The investigators will recruit patients at 30 days of age to 1 year of age with those types of heart disease whose surgical approach has a high probability of myocardial resection.
  • Diagnosis of ToF/PS or other types of heart disease that have a high likelihood of requiring surgery that involves routine resection of myocardium that becomes available for research

Exclusion criteria

Exclusion Criteria:

  • Patients with low chance of having resection of myocardium as part of their surgical care.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    N15-thymidine

    Study participants will receive thymidine preparations for pre-defined blocks of time prior to the scheduled routine resection of myocardium.

    Other: N15-thymidine

Interventions

  • OtherN15-thymidine

    50mg/kg (oral administration)

06

What researchers measure

Primary outcomes

  1. Percentage of labeled cardiomyocytes for each patient

    The investigators will use, multi-isotope imaging mass spectrometry (MIMS) to quantify the generation of new cardiomyocytes by examining myocardial samples that are routinely resected and discarded during cardiac surgery. Investigators will then calculate the percentage of labeled, i.e. newly generated, cardiomyocytes, for each patient. The data from the analysis of myocardial samples will be the test results. Investigators will first compare these results with technical controls.

    Time frame: 6 months

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 9 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Sep 19, 2024
StartActual
May 15, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06587165
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), California Institute of Technology
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
May 15, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Rashida Blackwood, BS, MPH
Contact
rab4029@med.cornell.edu
646-962-9036
Bernhard Kuhn, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion